OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION: THERAPEUTIC IMPLICATIONS. JUNE 18-21, 1989, ROCKVILLE, MD

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION: THERAPEUTIC IMPLICATIONS. JUNE 18-21, 1989, ROCKVILLE, MD

Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression: Therapeutic Implications. June 18-21, 1989, Rockville, MD, National Cancer Institute, National Institute of Allergy and Infectious Diseases, 1989.. Unique Identifier : AIDSLINE ICDB/90660171
Anonymous; No affiliation given

Abstract: A symposium on therapeutic implications of oligodeoxynucleotides as antisense inhibitors of gene expression, held June 18-21, 1989, in Rockville, MD, was cosponsored by NCI and the National Institute of Allergy and Infectious Diseases. Speakers' presentations and poster sessions are summarized. Topics include the following: the antisense approach, control of gene expression by oligodeoxynucleotides covalently linked to intercalating agents, synthesis (DNA-containing phosphorodithioate internucleotide linkages, oligonucleotide p-chiral analogs, covalently linked oligo analogs, oligoribonucleotides), oligo analogs as potential therapeutic agents, FDA definitions, progress in pharmacology and toxicology, characterization of oligonucleotide transport into living cells, modification of antisense oligonucleotides to improve cellular uptake, inhibition of expression (translation arrest by oligos, RNase H activity, behavior of alpha and beta oligos, effect of phosphorothioate homo-oligodeoxynucleotides on herpes simplex virus type 2-induced DNA polymerase), DNA as a site of action (unusual DNA structures in vivo and in vitro, structural basis for specificity in triple helix formation, inhibition of sequence-specific DNA-binding proteins by oligonucleotide-directed triple helix formation, analysis of the sequence selectivity and cellular application of triplex-forming oligonucleotides as gene-specific reagents), and applications (oligonucleoside methylphosphonates; comparative inhibition by different antisense oligonucleotide analogs; inhibition of tick-borne viral encephalitis expression using covalently linked oligonucleotide analogs; optimum targets for antisense inhibition in human c-myc mRNA; inhibition of HIV; inhibition by phosphorothioate oligodeoxynucleotides in cell-free, viral, and oncogene systems; inhibition of expression in trypanosomes).

Keywords: Animal Gene Expression Regulation, Neoplastic/*DRUG EFFECTS Human Neoplasms/GENETICS/*THERAPY Oligonucleotides/*THERAPEUTIC USE MONOGRAPH
910228
M9120723

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .